VELARU MANDATE EXHIBIT PACK — GXP / FDA 21 CFR PART 11 PHARMA
Jurisdiction: India (in)
Modality: Text / Chat
Program: Velaru GxP / FDA 21 CFR Part 11 Pharma · India (galactic_gxp_in)
Product ID: gxp:in:bundle:text
Vertical: gxp
Generated: 2026-08-22T18:34:48.641289Z
Authority: India DPDPA Pack — GxP Electronic Records Integrity Pack
Deadline: DPDPA 2023 enforcement + SEBI AI circular
Velaru verify: https://velaru.xyz/verify

EXHIBIT A — AI INVENTORY
[
  {
    "named_entity": "Velari",
    "slug": "velari",
    "ai_use_case": "AI-assisted GxP / FDA 21 CFR Part 11 Pharma decisions",
    "vertical": "gxp",
    "risk_tier": "elevated",
    "external_validation": "Velaru independent receipt verification",
    "handler_receipt_lock": "https://velaru.onrender.com/r/4c58eac890bfd031ce2189de5a1ca9ea292a0c837f5f535daf164aef34f31e53",
    "compliance_state": "non_compliant",
    "asymmetry_grade": "A",
    "found_scripture_export": "https://velaru.xyz/bundle/pre-dispute/d8fb129c0c0c78d05256/export.txt",
    "diligence_url": "https://velaru.xyz/diligence/velari"
  },
  {
    "named_entity": "LinkAudit Test",
    "slug": "linkaudit-test",
    "ai_use_case": "AI-assisted GxP / FDA 21 CFR Part 11 Pharma decisions",
    "vertical": "gxp",
    "risk_tier": "elevated",
    "external_validation": "Velaru independent receipt verification",
    "handler_receipt_lock": "https://velaru.onrender.com/r/58ddedd1974156453bc55daef6a9857d8570d56388becbb2a80bf5bac76b771b",
    "compliance_state": "non_compliant",
    "asymmetry_grade": "A",
    "found_scripture_export": "https://velaru.xyz/bundle/pre-dispute/78aa6e3f3a84cf1a88c0/export.txt",
    "diligence_url": "https://velaru.xyz/diligence/linkaudit-test"
  },
  {
    "named_entity": "Link Audit Co",
    "slug": "link-audit-co",
    "ai_use_case": "AI-assisted GxP / FDA 21 CFR Part 11 Pharma decisions",
    "vertical": "gxp",
    "risk_tier": "elevated",
    "external_validation": "Velaru independent receipt verification",
    "handler_receipt_lock": "https://velaru.onrender.com/r/d00533b7b6c0495802b4250abd5c29f60bd9f2ad3fb141bba2d9a5afee5f5542",
    "compliance_state": "non_compliant",
    "asymmetry_grade": "A",
    "found_scripture_export": "https://velaru.xyz/bundle/pre-dispute/fea572f3996c4b963779/export.txt",
    "diligence_url": "https://velaru.xyz/diligence/link-audit-co"
  }
]

EXHIBIT B — GOVERNANCE FRAMEWORK
{
  "framework": "Velaru Mandate Registry \u2014 GxP / FDA 21 CFR Part 11 Pharma",
  "exhibit_authority": "India DPDPA Pack \u2014 GxP Electronic Records Integrity Pack",
  "regulatory_frameworks": [
    "FDA 21 CFR Part 11",
    "FDA 21 CFR Part 211 GMP",
    "ICH E6 GCP",
    "ICH Q10 Pharmaceutical Quality System",
    "EU GMP Annex 11",
    "WHO GMP guidelines",
    "FDA 483 observation risk",
    "DPDPA 2023",
    "SEBI LODR AI disclosure",
    "RBI AI guidelines",
    "IT Rules 2026"
  ],
  "standards_alignment": [
    "POSS-2",
    "DRP-1",
    "TCB",
    "FRE 707 pre-compliance",
    "ISO 42001"
  ],
  "human_oversight": "release manufacturing batch",
  "third_party_verification": "https://velaru.xyz/verify (operator-independent)",
  "data_lineage": "Hash-chained Ed25519 receipts; optional RFC3161 + external anchor",
  "mirror_trap": "QA releases batch on AI recommendation without hash-chained record \u2014 batch recall insurance void. \u00b7 Fastest AI adoption market \u2014 US vendor contracts don't cover DPDPA fines.",
  "chain_integrity": {
    "depth": 496,
    "invariant_holds": true
  }
}

EXHIBIT D — DATA INPUTS & VALIDATION
{
  "data_validation_method": "Cryptographic receipt per AI decision; public verify without trusting deployer, vendor, or Velaru operator",
  "bias_testing_proxy": "Asymmetry score from live chain signals",
  "model_change_control": "Policy lock registry \u2014 criteria hash frozen pre-dispute",
  "logging_retention": "90-day pre-dispute window minimum; permanent verify permalinks",
  "external_validator": "Nisaba LLC / Velaru",
  "validator_independence": "Client-side Ed25519 verify; BYOK tri-receipt optional",
  "headline_stat": "Delete audit trail before inspection = automatic consent decree pattern",
  "global_leaders_addressed": [
    "FDA",
    "Merck",
    "Lonza",
    "Waters Corporation",
    "ISPE",
    "SEBI",
    "RBI",
    "Zerodha"
  ]
}

MIRROR TRAP (regulatory insight)
QA releases batch on AI recommendation without hash-chained record — batch recall insurance void. · Fastest AI adoption market — US vendor contracts don't cover DPDPA fines.

NERVE CARDS — WHY GLOBAL LEADERS CARE
[
  {
    "title": "Deviation reports",
    "body": "AI flags GMP deviation \u2014 without receipt, QA cannot prove when they knew.",
    "source": "vertical"
  },
  {
    "title": "Annex 11 EU",
    "body": "European GMP requires same integrity \u2014 global pharma needs one primitive.",
    "source": "vertical"
  },
  {
    "title": "Recall insurance",
    "body": "Insurers deny recall claims when electronic records integrity violated.",
    "source": "vertical"
  },
  {
    "title": "[India] SEBI listed cos",
    "body": "Material AI risk disclosure to stock exchange \u2014 receipt satisfies audit trail.",
    "source": "jurisdiction"
  },
  {
    "title": "[India] UPI + AI",
    "body": "India digital payments + AI fraud \u2014 RBI expects explainable decline decisions.",
    "source": "jurisdiction"
  },
  {
    "title": "[Text / Chat] Modality hook",
    "body": "Baseline \u2014 all frameworks apply to text decisions.",
    "source": "modality"
  }
]

BOOK SUMMARY: {
  "total_insureds": 3,
  "compliant": 0,
  "grace_period": 0,
  "non_compliant": 3,
  "expired": 0,
  "not_enrolled": 0,
  "compliant_pct": 0.0
}

TAM / EXPOSURE: Every GMP facility globally · Part 11 is law today
INSURANCE LINES: Product recall, Pharma E&O

DISCLAIMER: External validation evidence pack — not legal advice, not filed rate approval.